WIXELA Drug Patent Profile
✉ Email this page to a colleague
When do Wixela patents expire, and when can generic versions of Wixela launch?
Wixela is a drug marketed by Mylan and is included in one NDA.
The generic ingredient in WIXELA is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Wixela
A generic version of WIXELA was approved as fluticasone propionate; salmeterol xinafoate by HIKMA on December 17th, 2020.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for WIXELA?
- What are the global sales for WIXELA?
- What is Average Wholesale Price for WIXELA?
Summary for WIXELA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for WIXELA |
| DailyMed Link: | WIXELA at DailyMed |
US Patents and Regulatory Information for WIXELA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan | WIXELA INHUB | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208891-001 | Jan 30, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Mylan | WIXELA INHUB | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208891-002 | Jan 30, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Mylan | WIXELA INHUB | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208891-003 | Jan 30, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
